Wagovii will be available for adults with at least one weight-related condition. The criteria is obstructive sleep apnea, heart disease and a body mass index of at least 35. There's also advice that in exceptional cases, some people whose BMI is actually 30 or higher might also be able to access the drug. But it really is people who are at the higher end of the BMI scale.
Ian Sample speaks to Guardian science correspondent Nicola Davis about the news that Wegovy, an appetite suppressant popular with celebrities in the US, will soon be sold at UK pharmacies. It’s a prescription drug aimed at helping people with obesity lose weight, but some argue it doesn’t tackle the root cause of the disease. Help support our independent journalism at
theguardian.com/sciencepod